Hemanext ONE is an FDA-authorized system that mitigates red blood cell storage lesion through hypoxic storage. This technology preserves RBC quality and functionality, aiming to improve therapeutic outcomes for transfusion recipients.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The storage of red blood cells (RBCs) leads to a phenomenon known as storage lesion, which degrades their quality and reduces their therapeutic efficacy. This degradation can negatively impact patient outcomes and the overall value of blood transfusions within the healthcare system.
Solution
Hemanext ONE is an FDA-authorized processing and storage technology designed to mitigate the RBC storage lesion. By employing a hypoxic storage methodology, the system aims to preserve RBC quality, functionality, and viability throughout the storage period. This innovation seeks to enhance the therapeutic impact of transfused blood, thereby improving patient care and optimizing the utilization of blood products. The technology is intended to set a new standard of care for patients requiring blood transfusions.
Target Audience
The primary customers are healthcare providers, blood banks, and transfusion medicine professionals who manage and utilize blood products for patient care.
Features
- FDA-authorized processing and storage system for red blood cells (RBCs).
- Technology specifically designed to mitigate the RBC storage lesion.
- Utilizes hypoxic storage conditions to preserve RBC quality and viability.
- Aims to enhance the functional capacity of stored RBCs.
- Supports the optimization of therapeutic outcomes for transfusion recipients.
- Developed to improve the overall value of blood products in healthcare.